ArticleEndocrine2025
Dynamic 4 dimensional contrast enhanced MRI for localization in primary hyperparathyroidism.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIt can be challenging to localize the lesions in certain cases of primary hyperparathyroidism. Recently, it has been proposed that assessing the localization of parathyroid lesions with dynamic images enhances the diagnostic power of standard MRI (magnetic resonance imaging) due to the hypervascular structure of these lesions. In this study, we aimed to evaluate the success of four-dimensional dynamic perfusion MRI (4D MRI) in localizing parathyroid lesions.
methodsThirty patients who underwent 4-dimensional dynamic MRI diagnosed with primary hyperparathyroidism and indications for surgery, whose USG (ultrasonography) and/or Tc 99m sestamibi SPECT scan were negative or discordant, were included. The sensitivity and positive predictive values (PPV) were calculated for each imaging modality.
resultsOf the 30 patients, 29 had parathyroid adenoma, and one had parathyroid hyperplasia in histopathologic examination. 4D MRI accurately identified the location of parathyroid lesions in 25 of 30 patients (sensitivity 83.3%, PPV 96.1%), whereas USG successfully identified the lesion location in 21 patients (sensitivity 70%, PPV 91.3%) and Tc 99m sestamibi SPECT scan in 17 patients (sensitivity 56.7%, PPV 94.4%). The sensitivity of the combination of three imaging modalities was found to be 96.7%.
conclusion4D MRI can be utilized as a complementary imaging modality to localize parathyroid lesions, offering the advantage of no ionizing radiation, especially when USG and/or Tc 99m sestamibi SPECT scans cannot reliably identify them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.